Inferring Pathway Activity toward Precise Disease Classification

The advent of microarray technology has made it possible to classify disease states based on gene expression profiles of patients. Typically, marker genes are selected by measuring the power of their expression profiles to discriminate among patients of different disease states. However, expression-based classification can be challenging in complex diseases due to factors such as cellular heterogeneity within a tissue sample and genetic heterogeneity across patients. A promising technique for coping with these challenges is to incorporate pathway information into the disease classification procedure in order to classify disease based on the activity of entire signaling pathways or protein complexes rather than on the expression levels of individual genes or proteins. We propose a new classification method based on pathway activities inferred for each patient. For each pathway, an activity level is summarized from the gene expression levels of its condition-responsive genes (CORGs), defined as the subset of genes in the pathway whose combined expression delivers optimal discriminative power for the disease phenotype. We show that classifiers using pathway activity achieve better performance than classifiers based on individual gene expression, for both simple and complex case-control studies including differentiation of perturbed from non-perturbed cells and subtyping of several different kinds of cancer. Moreover, the new method outperforms several previous approaches that use a static (i.e., non-conditional) definition of pathways. Within a pathway, the identified CORGs may facilitate the development of better diagnostic markers and the discovery of core alterations in human disease

Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014

The XXII World Congress of Psychiatric Genetics, sponsored by the International Society of Psychiatric Genetics, took place in Copenhagen, Denmark, on 12-16 October 2014. A total of 883 participants gathered to discuss the latest findings in the field. The following report was written by student and postdoctoral attendees. Each was assigned one or more sessions as a rapporteur. This manuscript represents topics covered in most, but not all of the oral presentations during the conference, and contains some of the major notable new findings reported

A critical evaluation of network and pathway based classifiers for outcome prediction in breast cancer

Recently, several classifiers that combine primary tumor data, like gene expression data, and secondary data sources, such as protein-protein interaction networks, have been proposed for predicting outcome in breast cancer. In these approaches, new composite features are typically constructed by aggregating the expression levels of several genes. The secondary data sources are employed to guide this aggregation. Although many studies claim that these approaches improve classification performance over single gene classifiers, the gain in performance is difficult to assess. This stems mainly from the fact that different breast cancer data sets and validation procedures are employed to assess the performance. Here we address these issues by employing a large cohort of six breast cancer data sets as benchmark set and by performing an unbiased evaluation of the classification accuracies of the different approaches. Contrary to previous claims, we find that composite feature classifiers do not outperform simple single gene classifiers. We investigate the effect of (1) the number of selected features; (2) the specific gene set from which features are selected; (3) the size of the training set and (4) the heterogeneity of the data set on the performance of composite feature and single gene classifiers. Strikingly, we find that randomization of secondary data sources, which destroys all biological information in these sources, does not result in a deterioration in performance of composite feature classifiers. Finally, we show that when a proper correction for gene set size is performed, the stability of single gene sets is similar to the stability of composite feature sets. Based on these results there is currently no reason to prefer prognostic classifiers based on composite features over single gene classifiers for predicting outcome in breast cancer

Deciphering transcriptional regulation in cancer cells and development of a new method to identify key transcriptional regulators and their target genes

Cancer cells accumulate genetic changes during carcinogenesis. The dimension of these changes range from point mutations to large chromosomal aberrations. It has been widely accepted that essential genetic programs are thereby dysregulated that normally would prevent uncontrolled cellular division and growth. Transcription factors (TFs) are key proteins of gene regulation and are frequently associated with genetic pathologies, e.g. MYCN in neuroblastomas (NBs). Research on gene regulation -in general or condition-specific- thus is a central aspect in cancer research, and it is also the focus of my work. In a carcinogenesis model of NBs without MYCN-amplification, mutations of chromosome 11q (11q-CNA) are suspected to critically influence tumor development. We were able to refine this model by means of gene expression analysis on 11q-CNA in NBs with different clinical outcome. Gene expression profiles of NBs with unfavorable progression differed significantly between tumors with and without 11q-CNA, whereas 11q-CNA in NBs with favorable outcome is apparently compensated by a yet unknown mechanism. The TF-encoding gene CAMTA1 is located on the chromosomal region 1p, which is frequently deleted in NBs. In vitro experiments with ectopic induction of CAMTA1 yielded CAMTA1-regulated genes with different gene expression profiles that were functionally associated by enrichment analyses with cell cycle regulation and neuronal differentiation. The suggested role of CAMTA1 as a tumor suppressor gene was confirmed by additional in vivo experiments. Furthermore, we studied the effect of MYC and MYCN in NBs without MYCN-amplification and found that these TF also strongly regulate a large number of common target genes according to their own gene expression in these tumors. Promoter analyses and chromatin immunoprecipitation additionally supported the regulation of the determined target genes by MYC/MYCN. The genome-wide application of promoter and enrichment analyses on gene expression data from mouse models enabled us to predict target TFs of Rage signaling. E2f1 and E2f4 were validated experimentally as components of the Rage-dependent gene regulatory network. Finally, we used our experience from gene expression analysis to develop a novel machine learning method to precisely predict TF target gene relationships in human. We combined results from a genome-wide correlation meta-analysis on 4064 microarray gene expression profiles and promoter analyses on TF binding sites with known regulatory interactions between TFs and target genes in our approach. Our method outperformed other comparable methods in human, as we improved shortcomings of other algorithms specifically for higher eukaryotes, in particular the frequently (erroneously) assumed correlation between the mRNA expression of TFs and their target genes. We made our method freely available as a software package with multiple applications like the identification of key TFs in a multiplicity of cellular systems (e.g. cancer cells)

Functional and evolutionary implications of in silico gene deletions

Understanding how genetic modifications, individual or in combination, affect organismal fitness or other phenotypes is a challenge common to several areas of biology, including human health & genetics, metabolic engineering, and evolutionary biology. The importance of a gene can be quantified by measuring the phenotypic impact of its associated genetic perturbations "here and now", e.g. the growth rate of a mutant microbe. However, each gene also maintains a historical record of its cumulative importance maintained throughout millions of years of natural selection in the form of its degree of sequence conservation along phylogenetic branches. This thesis focuses on whether and how the phenotypic and evolutionary importance of genes are related to each other. Towards this goal, I developed a new approach for characterizing the phenotypic consequences of genetic modifications in genome-scale biochemical networks using constraint-based computational models of metabolism. In particular, I investigated the impact of gene loss events on fitness in the model organism Saccharomyces cerevisiae, and found that my new metric for estimating the cost of gene deletion correlates with gene evolutionary rate. I found that previous failures to uncover this correlation using similar techniques may have been the result of an incorrect assumption about how isoenzymes deletions affect the reaction they catalyze. I next hypothesized that the improvement my metric showed in predicting the cost of isoenzyme loss could translate into an improved capacity to predict the impact of pairs of gene deletions involving isoenzymes. Studies of such pair-wise genetic perturbations are important, because the extent to which a genetic perturbation modifies any given phenotype is often dependent on the genetic background upon which it has been performed. This lack of independence within sets of perturbations is termed epistasis. My results showed that, indeed, the new metric displays an increased capacity to predict epistatic interactions between pairs of genes. In addition to shedding light on the relationship between the functional and evolutionary importance of genes, further developments of our approach may lead to better prediction of gene knockout phenotypes, with applications ranging from metabolic engineering to the search for gene targets for therapeutic applications

Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Upregulation of antioxidant genes correlates with regression of melanoma malignancy and with malignant progression when downregulated

Reactive oxygen species (ROS) are implicated in tumor transformation. The antioxidant system (AOS) protects cells from ROS damage. However, it is also hijacked by cancers cells to proliferate within the tumor. Thus, identifying proteins altered by redox imbalance in cancer cells is an attractive prognostic and therapeutic tool. Gene expression microarrays in A375 melanoma cells with different ROS levels after overexpressing catalase were performed. Dissimilar phenotypes by differential compensation to hydrogen peroxide scavenging were generated. The melanotic A375-A7 (A7) upregulated TYRP1, CNTN1 and UCHL1 promoting melanogenesis. The metastatic A375-G10 (G10) downregulated MTSS1 and TIAM1, proteins absent in metastasis. Moreover, differential coexpression of AOS genes (EPHX2, GSTM3, MGST1, MSRA, TXNRD3, MGST3 and GSR) was found in A7 and G10. Their increase in A7 improved its AOS ability and therefore, oxidative stress response, resembling less aggressive tumor cells. Meanwhile, their decrease in G10 revealed a disruption in the AOS and therefore, enhanced its metastatic capacity.These gene signatures, not only bring new insights into the physiopathology of melanoma, but also could be relevant in clinical prognostic to classify between non aggressive and metastatic melanomas.Fil: Bracalente, Candelaria. Comisión Nacional de Energía Atómica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ibañez, Irene Laura. Comisión Nacional de Energía Atómica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Berenstein, Ariel José. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Física; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física de Buenos Aires. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física de Buenos Aires; ArgentinaFil: Notcovich, Cintia. Comisión Nacional de Energía Atómica; ArgentinaFil: Cerda, María B.. Comisión Nacional de Energía Atómica. Gerencia Química. CAC; ArgentinaFil: Klamt, Fabio. Universidade Federal do Rio Grande do Sul; BrasilFil: Chernomoretz, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física de Buenos Aires. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física de Buenos Aires; ArgentinaFil: Durán, Hebe. Comisión Nacional de Energía Atómica; Argentin

Molecular targets of alcohol action: translational research for pharmacotherapy development and screening.

Alcohol abuse and dependence are multifaceted disorders with neurobiological, psychological, and environmental components. Research on other complex neuropsychiatric diseases suggests that genetically influenced intermediate characteristics affect the risk for heavy alcohol consumption and its consequences. Diverse therapeutic interventions can be developed through identification of reliable biomarkers for this disorder and new pharmacological targets for its treatment. Advances in the fields of genomics and proteomics offer a number of possible targets for the development of new therapeutic approaches. This brain-focused review highlights studies identifying neurobiological systems associated with these targets and possible pharmacotherapies, summarizing evidence from clinically relevant animal and human studies, as well as sketching improvements and challenges facing the fields of proteomics and genomics. Concluding thoughts on using results from these profiling technologies for medication development are also presented

METABOLIC MODELING AND OMICS-INTEGRATIVE ANALYSIS OF SINGLE AND MULTI-ORGANISM SYSTEMS: DISCOVERY AND REDESIGN

Computations and modeling have emerged as indispensable tools that drive the process of understanding, discovery, and redesign of biological systems. With the accelerating pace of genome sequencing and annotation information generation, the development of computational pipelines for the rapid reconstruction of high-quality genome-scale metabolic networks has received significant attention. These models provide a rich tapestry for computational tools to quantitatively assess the metabolic phenotypes for various systems-level studies and to develop engineering interventions at the DNA, RNA, or enzymatic level by careful tuning in the biophysical modeling frameworks. in silico genome-scale metabolic modeling algorithms based on the concept of optimization, along with the incorporation of multi-level omics information, provides a diverse array of toolboxes for new discovery in the metabolism of living organisms (which includes single-cell microbes, plants, animals, and microbial ecosystems) and allows for the reprogramming of metabolism for desired output(s). Throughout my doctoral research, I used genome-scale metabolic models and omics-integrative analysis tools to study how microbes, plants, animal, and microbial ecosystems respond or adapt to diverse environmental cues, and how to leverage the knowledge gleaned from that to answer important biological questions. Each chapter in this dissertation will provide a detailed description of the methodology, results, and conclusions from one specific research project. The research works presented in this dissertation represent important foundational advance in Systems Biology and are crucial for sustainable development in food, pharmaceuticals and bioproduction of the future. Advisor: Rajib Sah

Identification of novel targets for breast cancer by exploring gene switches on a genome scale

<p>Abstract</p> <p>Background</p> <p>An important feature that emerges from analyzing gene regulatory networks is the "switch-like behavior" or "bistability", a dynamic feature of a particular gene to preferentially toggle between two steady-states. The state of gene switches plays pivotal roles in cell fate decision, but identifying switches has been difficult. Therefore a challenge confronting the field is to be able to systematically identify gene switches.</p> <p>Results</p> <p>We propose a top-down mining approach to exploring gene switches on a genome-scale level. Theoretical analysis, proof-of-concept examples, and experimental studies demonstrate the ability of our mining approach to identify bistable genes by sampling across a variety of different conditions. Applying the approach to human breast cancer data identified genes that show bimodality within the cancer samples, such as estrogen receptor (ER) and ERBB2, as well as genes that show bimodality between cancer and non-cancer samples, where tumor-associated calcium signal transducer 2 (TACSTD2) is uncovered. We further suggest a likely transcription factor that regulates TACSTD2.</p> <p>Conclusions</p> <p>Our mining approach demonstrates that one can capitalize on genome-wide expression profiling to capture dynamic properties of a complex network. To the best of our knowledge, this is the first attempt in applying mining approaches to explore gene switches on a genome-scale, and the identification of TACSTD2 demonstrates that single cell-level bistability can be predicted from microarray data. Experimental confirmation of the computational results suggest TACSTD2 could be a potential biomarker and attractive candidate for drug therapy against both ER+ and ER- subtypes of breast cancer, including the triple negative subtype.</p